These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...
Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...
Bayer has taken a further stake in New York ... our business strategy with the ambition to actively shape the future of healthcare. “We are convinced that a data-driven approach will empower ...
Leadership Strategist Dan Pontefract covers leadership and culture. Heike Prinz of Bayer's Board of Management recently articulated the company's predicament, stating, "Bayer is currently in a ...
Bayer has entered into an alliance with Impli, tapping into the start-up's implantable hormone-monitoring platform, which has potential in fertility treatment and other indications. Impli's ...
It aspires to be seen as a partner of choice for key customers in priority markets by creating best-in-class joint business opportunities that provide a win for Bayer, its customers, the category and ...
Bayer’s BlueRock Therapeutics outfit announced Jan. 13 in tandem with the annual J.P. Morgan Healthcare Conference. The phase 3 trial, dubbed exPDite-2, is expected to enroll 102 people with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback